{"id":"immuno-oncology-io","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Nivolumab","action":"Monitor","effect":"Increased risk of pneumonitis"},{"drug":"Ipilimumab","action":"Monitor","effect":"Increased risk of colitis, dermatitis, and endocrinopathy"},{"drug":"Pembrolizumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Nivolumab + Ipilimumab","action":"Monitor","effect":"Increased risk of colitis, dermatitis, and endocrinopathy"},{"drug":"Nivolumab + Pembrolizumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Pembrolizumab + Ipilimumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Nivolumab + Ipilimumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Ipilimumab + Nivolumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Atezolizumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Nivolumab + Atezolizumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Pembrolizumab + Avelumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Nivolumab + Avelumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Pembrolizumab + Durvalumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Nivolumab + Durvalumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Pembrolizumab + Tremelimumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Nivolumab + Tremelimumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Pembrolizumab + Nivolumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Nivolumab + Pembrolizumab + Ipilimumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Pembrolizumab + Nivolumab + Ipilimumab","action":"Monitor","effect":"Increased risk of pneumonitis, colitis, and hepatitis"},{"drug":"Nivolumab + Atezolizumab + Bevacizumab","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Atezolizumab + Bevacizumab","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Avelumab + Bevacizumab","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Avelumab + Bevacizumab","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Durvalumab + Bevacizumab","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Durvalumab + Bevacizumab","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Tremelimumab + Bevacizumab","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Tremelimumab + Bevacizumab","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Atezolizumab + Bevacizumab + Axitinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Atezolizumab + Bevacizumab + Axitinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Avelumab + Bevacizumab + Axitinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Avelumab + Bevacizumab + Axitinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Durvalumab + Bevacizumab + Axitinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Durvalumab + Bevacizumab + Axitinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Tremelimumab + Bevacizumab + Axitinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Tremelimumab + Bevacizumab + Axitinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Atezolizumab + Bevacizumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Atezolizumab + Bevacizumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Avelumab + Bevacizumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Avelumab + Bevacizumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Durvalumab + Bevacizumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Durvalumab + Bevacizumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Tremelimumab + Bevacizumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Tremelimumab + Bevacizumab + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Atezolizumab + Bevacizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Atezolizumab + Bevacizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Avelumab + Bevacizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Avelumab + Bevacizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Durvalumab + Bevacizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Durvalumab + Bevacizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Tremelimumab + Bevacizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Tremelimumab + Bevacizumab + Lenvatinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Atezolizumab + Bevacizumab + Axitinib + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Atezolizumab + Bevacizumab + Axitinib + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Avelumab + Bevacizumab + Axitinib + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Pembrolizumab + Avelumab + Bevacizumab + Axitinib + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"},{"drug":"Nivolumab + Durvalumab + Bevacizumab + Axitinib + Cabozantinib","action":"Monitor","effect":"Increased risk of hypertension, diarrhea, and fatigue"}],"commonSideEffects":[],"contraindications":["active, potentially life-threatening autoimmune disease","requiring >10 mg daily prednisone equivalent"],"specialPopulations":{"Pregnancy":"The use of ICIs during pregnancy is discouraged due to the absence of safety data from large-scale studies exploring the toxic effects of these agents during pregnancy. However, in this cohort study of 91 individuals exposed to ICIs during pregnancy, ICI exposure was not associated with overreporting of specific adverse pregnancy, fetal, and/or newborn outcomes compared with other anticancer treatments. However, due to possible rare immune-related neonatal adverse events, ICI use in pregnant women should be avoided when possible.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=immuno-oncology-io","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:55:58.597251+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:56:12.468825+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:56:04.080288+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:55:58.669711+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=immuno-oncology-io","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:56:04.482415+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4574125/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:05.253892+00:00"}},"allNames":"immuno-oncology (io)","offLabel":[],"timeline":[],"aiSummary":"Pfizer's Immuno-oncology-io is a marketed melanoma treatment with a key composition patent expiring in 2028. The drug competes in the crowded PD-1 and PD-L1 inhibitor space, where it faces strong competition from established players such as Merck’s KEYTRUDA and Roche’s TECENTRIQ. The primary risk is the intense competition, which may impact market share and revenue growth.","brandName":"Immuno-oncology (IO)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for this drug is not specified on Wikipedia, making it challenging for healthcare professionals to understand its pharmacological properties and potential interactions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":1301,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"","revenueCurrency":"USD","peakSalesEstimate":"","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:46:17.511584","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=immuno-oncology-io","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=immuno-oncology-io","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:56:12.468940+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"KEYTRUDA","company":"Merck","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"},{"name":"TECENTRIQ","company":"Roche","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-L1 pathway to enhance the immune system's ability to fight cancer"},{"name":"Jemperli","company":"GSK","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"},{"name":"ZG005","company":"Suzhou Zelgen Biopharmaceuticals","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"},{"name":"C5252","company":"CStone Pharmaceuticals","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"},{"name":"Balstilimab","company":"Incyte Corporation","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"},{"name":"INCB 099280","company":"Incyte Corporation","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"},{"name":"Rilvegostomig","company":"Agenus","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"},{"name":"Sugemalimab","company":"BeiGene","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"},{"name":"Sasanlimab","company":"Incyte Corporation","advantage":"Competes with PD-1 and PD-L1 Inhibitors by blocking the PD-1 pathway to enhance the immune system's ability to fight cancer"}],"genericName":"immuno-oncology-io","indications":{"approved":[{"name":"Melanoma","regulator":"FDA"},{"name":"Non-Small Cell Lung Cancer (NSCLC)","regulator":"FDA"},{"name":"Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Head and Neck Squamous Cell Carcinoma (HNSCC)","regulator":"FDA"},{"name":"Urothelial Carcinoma (UC)","regulator":"FDA"},{"name":"Microsatellite Instability-High (MSI-H) Cancer","regulator":"FDA"},{"name":"Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Classical Hodgkin Lymphoma (cHL)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Melanoma","regulator":"FDA"},{"name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","regulator":"FDA"},{"name":"Adjuvant Treatment of Colorectal Cancer","regulator":"FDA"},{"name":"Adjuvant Treatment of Renal Cell Carcinoma (RCC)","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06630273","phase":"","title":"Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics","status":"NOT_YET_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2026-04-30","conditions":"Carcinoma","enrollment":120},{"nctId":"NCT07000149","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma","enrollment":1116},{"nctId":"NCT04895748","phase":"PHASE1","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Carcinoma, Renal Cell","enrollment":40},{"nctId":"NCT05858749","phase":"","title":"A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-06-20","conditions":"Metastatic Renal Cell Carcinoma","enrollment":494},{"nctId":"NCT07174388","phase":"","title":"A Study in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"N-Power Medicine","startDate":"2026-01-07","conditions":"Non Small Cell Lung Cancer","enrollment":550},{"nctId":"NCT04567615","phase":"PHASE2","title":"A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-02-04","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult","enrollment":266},{"nctId":"NCT06026410","phase":"PHASE1","title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2023-10-18","conditions":"Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)","enrollment":300},{"nctId":"NCT06725368","phase":"PHASE2","title":"Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"RECRUITING","sponsor":"Centre Paul Strauss","startDate":"2025-01-24","conditions":"Head and Neck Cancer","enrollment":46},{"nctId":"NCT03610711","phase":"PHASE1, PHASE2","title":"REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-03-06","conditions":"Gastroesophageal Cancer, Immune Checkpoint Inhibition","enrollment":21},{"nctId":"NCT04500535","phase":"","title":"A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-09-28","conditions":"Lung Cancer","enrollment":535},{"nctId":"NCT06117891","phase":"","title":"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-11-27","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT07215962","phase":"","title":"Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-11-22","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":300},{"nctId":"NCT04931654","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-28","conditions":"Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":136},{"nctId":"NCT04577963","phase":"PHASE1, PHASE2","title":"A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hutchmed","startDate":"2021-08-09","conditions":"Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult","enrollment":52},{"nctId":"NCT05543629","phase":"PHASE1, PHASE2","title":"A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-10-04","conditions":"Advanced Solid Tumors, Non-small Cell Lung Cancer","enrollment":36},{"nctId":"NCT04957160","phase":"","title":"Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination","status":"COMPLETED","sponsor":"Ipsen","startDate":"2021-09-09","conditions":"Advanced Renal Cell Carcinoma (aRCC)","enrollment":281},{"nctId":"NCT04020185","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of IMSA101 in Refractory Malignancies","status":"COMPLETED","sponsor":"ImmuneSensor Therapeutics Inc.","startDate":"2019-09-23","conditions":"Solid Tumor, Adult","enrollment":40},{"nctId":"NCT04375150","phase":"","title":"Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-12-02","conditions":"Renal Cell Carcinoma (RCC)","enrollment":355},{"nctId":"NCT04641936","phase":"","title":"Urine Omics Predicting IO Therapy Responses in mUC Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-12-17","conditions":"Metastatic Urothelial Carcinoma","enrollment":600},{"nctId":"NCT05502913","phase":"PHASE2","title":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","status":"RECRUITING","sponsor":"Soroka University Medical Center","startDate":"2023-09-01","conditions":"Metastatic Lung Cancer","enrollment":80},{"nctId":"NCT04606940","phase":"","title":"Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-19","conditions":"Head and Neck Cancer, Advanced Cancer, Metastatic Cancer","enrollment":18},{"nctId":"NCT04712305","phase":"","title":"Urine Omics Predicting IO Therapy Responses in mRCC Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-01-04","conditions":"Metastatic Renal Cell Carcinoma","enrollment":400},{"nctId":"NCT03336567","phase":"","title":"Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-12-04","conditions":"Neoplasms","enrollment":40}],"_emaApprovals":[{"date":"","name":"Immuno-oncology (IO)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4574125","moleculeType":"Unknown","molecularWeight":"212.22"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4574125"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":8,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:46:17.534457+00","biosimilarFilings":[],"recentPublications":[{"date":"2025 Mar 15","pmid":"39919914","title":"Research progress in bifunctional small molecules for cancer immunotherapy.","journal":"European journal of medicinal chemistry"},{"date":"2024 Aug 31","pmid":"39280655","title":"Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data.","journal":"Translational andrology and urology"},{"date":"2024 Feb 29","pmid":"38496701","title":"Dual immuno-oncology agents as neoadjuvant therapy for patients with resectable non-small cell lung cancer.","journal":"Translational lung cancer research"},{"date":"2023","pmid":"37795437","title":"Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.","journal":"Frontiers in oncology"},{"date":"2023 Jan 30","pmid":"36760380","title":"Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review.","journal":"Translational cancer research"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:56:12.468940+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}